The seed round was led by Parkwalk Advisors to support team expansion and product development.
"We are looking to interrupt a marketplace dominated by technologies reliant solely on sound, vision and increasingly, touch. Our sense of smell has the power to evoke long-forgotten memories, bring food to life, calm us down and enrich our lives. We create smell technologies that can be used across a range of innovative contexts. From leading healthcare research to artistic and immersive experiences, our products offer a total digital command over scent and smell."
HydrogenOne Capital Growth led the Series B round with support from IP Group, Parkwalk Advisors, BGF, and the UCL Technology Fund.
"Hydrogen, through its green production from electrolysis or its use in fuel cells to provide clean power, is critical for the transition to net zero. Bramble Energy brings a fundamentally different approach to these technologies, unlocking the deployment of hydrogen faster, more flexibly and at scale. We are delighted to contribute substantially to this significant funding round which will take Bramble to the next stage."
The financing round was co-led by Boehringer Ingelheim Venture Fund and Parkwalk Advisors, with participation from Tencent and Oxford University Innovation Fund.
"Over the past decade Brainomix has created the market for stroke AI imaging. As a spin-out from the University of Oxford it is an example of the UK's world-leading strengths in life sciences and AI-enabled medtech, combining expertise in clinical care and software development with more than 150 years' experience in the field across its leadership team."
The financing brings total Series A funds to $33m to advance the company cell reprogramming pipeline.
"We are delighted to see the continued support of our existing investors, as well as welcome new investors Astellas Venture Management and Dr Jonathan Milner, in support of the progression of our initial programs through to IND-enabling studies."
The financing round was led by Vulpes Investment Management with backing from existing investors to fund first in-human data acquisition.
"The current device market for brain aneurysms is valued at well over $1bn and is growing rapidly year-on-year. One of the biggest challenges when it comes to treating neurovascular disease is having devices with high efficacy whilst minimising adverse events. Studies show that often multiple attempts are made to place treatment devices, as they often have challenges of landing accurately, opening and maintaining position. This can lead to adverse events and multiple devices being used. Procedures typically cost over $50,000 to treat a brain aneurysm and a next generation flow diverter overcoming unmet needs, offers the chance for more effective, safer and cost effective treatments as well as allowing many more patients to benefit. We plan to use this funding to bring Oxford Endovascular’s ground-breaking technology to the next stage and gain clinical data from human studies."
